MLICM
ABCL icon

Metropolitan Life Insurance Company (MetLife)’s AbCellera Biologics ABCL Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,589
Closed -$87.4K – 2459
2023
Q1 		$87.4K Sell
11,589
-1,321
-10% -$12K ﹤0.01% 1065
2022
Q4 		$131K Buy
12,910
+238
+2% +$2.75K 0.01% 923
2022
Q3 		$125K Hold
12,672
– – 0.01% 888
2022
Q2 		$135K Buy
+12,672
New +$107K 0.01% 898

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ABCL Position: Q2 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 11,589 shares — an estimated $87.4K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ABCL in Q2 2022 and held it in 4 quarters. The position peaked at $135K in Q2 2022. 170 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 11,589 AbCellera Biologics shares in Q2 2023, an estimated $87.4K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in AbCellera Biologics in Q2 2022 and held it in 4 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s AbCellera Biologics position peaked at $135K in Q2 2022.
  • 170 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2023, filed 10 Aug 2023.